New research conducted on 2,700 patients in the U.S. indicates that a form of immunotherapy may provide hope for melanoma cancer that has spread to the brain. This new form of treatment, known as the Checkpoint Blockade does not involve chemotherapy, but rather "manipulates the patient's immune system so that it targets and destroys the melanoma cells." Study results indicate that patients receiving the CheckPoint Blockade experienced a rise in overall survival from 5.2 to 12.4 months.
To read more about this study, click here.
Source: Abate-Daga D. Ramello MC, Smalley I, Forsyth PA, Smalley KSM. The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol 2018 Jul; 153: 35-45.
No comments:
Post a Comment